Result of Shareholder Analysis
CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of June 30, 2026, identifying significant shareholders with interests of 3% or more in the company's ordinary share capital. The Miton UK Smaller Companies Fund holds the largest stake at 9.47%, followed by Mr. Andrew Webb with 9.22%, and Dr. Christopher McConville with 6.30%. Other substantial shareholders include Mr. Brian Murray (6.20%), Mr. David Lawton (5.07%), Zeus Dynamic Opportunities Fund (3.98%), Hobart Capital Markets LLP (3.57%), and Mr. John Rylands (3.02%).
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 30 June 2026, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company ("Ordinary Shares"):
| Shareholder | No. of Ordinary Shares | % interest in the ordinary share capital of the Company |
|---|---|---|
| Miton UK Smaller Companies Fund | 7,500,000 | 9.47% |
| Mr Andrew Webb | 7,297,190 | 9.22% |
| Dr Christopher McConville | 4,992,033 | 6.30% |
| Mr Brian Murray | 4,908,700 | 6.20% |
| Mr David Lawton | 4,012,220 | 5.07% |
| Zeus Dynamic Opportunities Fund | 3,150,000 | 3.98% |
| Hobart Capital Markets LLP | 2,830,000 | 3.57% |
| Mr John Rylands | 2,388,892 | 3.02% |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.